Published finding — does the expert body still believe it?
Durvalumab consolidation after chemoradiotherapy in stage III NSCLC significantly prolongs the median time to death or distant metastasis compared to placebo (23.2 months vs. 14.6 months; P<0.001).
TL;DR · AI-generated
Progression‐free survival was significantly longer with durvalumab than with placebo, and safety was similar between the groups, and the secondary end points also favored durvalsumab.
Author-implied confidence
93%
Status
DRAFT
Your position — does this noeme still stand given current evidence?
0% (impossible)
50%
100% (certain)
Proper-scoring-rule preview
Your position is kept on this device until you sign in.
Evidence stream
1 event · 1 snapshot
posterior drift
97% → 97% (0pp · 1 point)
Peer-reviewed paper
Apr 18, 2026
Expert reactions · 0
Sign in to post a take, cite a related claim, or flag a methodological concern.
No reactions yet. Be the first expert to post a take, cite a related claim, or flag a methodological concern.
Source publication
Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.
· openalex W2753065806 · s2 bc101251
Semantically related
Nearest claims in the expert-corpus vector space. Ordered by cosine distance — lower is closer.
0.0477
Durvalumab consolidation therapy after platinum-based chemoradiotherapy significantly improves median progression-free survival (16.8 months vs. 5.6 months; HR 0.52) compared to placebo in patients with unresectable stage III NSCLC who did not progress after chemoradiotherapy.
0.0725
Durvalumab consolidation therapy produces a significantly higher objective response rate than placebo (28.4% vs. 16.0%; P<0.001) in stage III NSCLC patients following chemoradiotherapy.
0.0899
Durvalumab consolidation after chemoradiotherapy will demonstrate a statistically significant overall survival benefit in the final analysis of the PACIFIC trial in stage III unresectable NSCLC.
0.1484
Grade 3 or 4 adverse events, including pneumonia, occur at similar rates in durvalumab-treated (29.9%) and placebo-treated (26.1%) stage III NSCLC patients receiving consolidation therapy after chemoradiotherapy.
0.1878
The KEYNOTE-189 trial's stated primary conclusion — Pembrolizumab plus chemotherapy improves overall survival in metastatic non-squamous NSCLC without targetable mutations. — replicates in independent cohorts.
0.2108
In previously untreated patients with unresectable stage III/IV melanoma, nivolumab plus ipilimumab achieves a median progression-free survival of 11.5 months versus 2.9 months with ipilimumab alone (HR 0.42, P<0.001).